Edward M. Kerwin
Expertise in
4
conditions

Dr. Edward M. Kerwin

Allergy and Immunology
Allergy And Asthma Center Of Southern Oregon, PC
2628 Clover St, 
Klamath Falls, OR 
 (2485.9 mi)
Accepting New Patients
Expertise in
4
conditions
Allergy And Asthma Center Of Southern Oregon, PC
2628 Clover St, 
Klamath Falls, OR 
 (2485.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Edward Kerwin is an Allergy and Immunologist in Klamath Falls, Oregon. Dr. Kerwin is highly rated in 4 conditions, according to our data. His top areas of expertise are Asthma, Allergic Rhinitis, Sinusitis, and Eosinophilic Asthma. Dr. Kerwin is currently accepting new patients.

His clinical research consists of co-authoring 109 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Allergy and Immunology
Licenses
Allergy & Immunology in OR
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  BridgeSpan
  •  PacificSource
  •  Moda Health
  •  Regence
  •  Prominence Health

Locations

ALLERGY AND ASTHMA CENTER OF SOUTHERN OREGON, PC
2628 Clover St, Klamath Falls, OR 97601
Other Locations
ALLERGY AND ASTHMA CENTER OF SOUTHERN OREGON, PC
3860 Crater Lake Ave, Suite A, Medford, OR 97504
ALLERGY AND ASTHMA CENTER OF SOUTHERN OREGON, PC
1813 W Harvard Ave, Suite 241, Roseburg, OR 97471

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis
A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2025
Intervention Type: Drug
Study Drug: Delgocitinib Cream
Study Phase: Phase 1
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg Once Daily on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma
Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg Once Daily on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma
Enrollment Status: Completed
Publish Date: January 17, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomised, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (Inclusive) Currently Uncontrolled on Inhaled Corticosteroids
A Randomised, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (Inclusive) Currently Uncontrolled on Inhaled Corticosteroids
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Drugs: Fluticasone Furoate, Vilanterol
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
A Phase 3b, 42-day, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin and Nebulized Formoterol Fumarate (PERFOROMIST®) Administered in Sequence and as a Combined Solution in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 3b, 42-day, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin and Nebulized Formoterol Fumarate (PERFOROMIST®) Administered in Sequence and as a Combined Solution in Subjects With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: February 24, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Three-period Cross-over Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts (Maleate and Acetate) Delivered Via the Concept1 Inhalation Device in Patients With Asthma
A Randomized, Double-blind, Placebo-controlled, Three-period Cross-over Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts (Maleate and Acetate) Delivered Via the Concept1 Inhalation Device in Patients With Asthma
Enrollment Status: Completed
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

109 Total Publications

Comparison of Systemic Exposure Between Epinephrine Delivered via Metered-Dose Inhalation and Intramuscular Injection.
Comparison of Systemic Exposure Between Epinephrine Delivered via Metered-Dose Inhalation and Intramuscular Injection.
Journal: Journal of aerosol medicine and pulmonary drug delivery
Published: August 29, 2024
Similar Doctors
Expertise in
9
conditions
Dr. Kevin W. Parks
Allergy and Immunology
Expertise in
9
conditions
Dr. Kevin W. Parks
Allergy and Immunology

Allergy And Asthma Center Of Southern Oregon, PC

2628 Clover St, 
Klamath Falls, OR 
541-858-1003
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Kevin Parks is an Allergy and Immunologist in Klamath Falls, Oregon. Dr. Parks is highly rated in 9 conditions, according to our data. His top areas of expertise are Sinusitis, Allergic Rhinitis, Leukocyte Adhesion Deficiency Type 1, and ICF Syndrome. Dr. Parks is currently accepting new patients.

Expertise in
0
conditions
Dr. Ryan B. Israelsen
Allergy and Immunology | Pediatrics | Pediatric Allergy and Immunology
Expertise in
0
conditions
Dr. Ryan B. Israelsen
Allergy and Immunology | Pediatrics | Pediatric Allergy and Immunology

Allergy And Asthma Center Of Southern Oregon, PC

3860 Crater Lake Ave, Suite A, 
Medford, OR 
 (55.1 mi)
541-858-1003
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ryan Israelsen is an Allergy and Immunologist and a Pediatrics provider in Medford, Oregon. His top areas of expertise are Allergic Rhinitis, Sinusitis, Primary Immunodeficiency (PID), and Ozena. Dr. Israelsen is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile